Science Corporation, a venture-backed company co-founded by Neuralink veteran Max Hodak, has secured $230 million in a Series C funding round, achieving a post-money valuation of $1.5 billion. While the broader venture capital landscape has recently focused heavily on artificial intelligence, Hodak is steering his startup toward bringing the first commercially viable brain-computer interface (BCI) to market. The company's immediate strategy centers on PRIMA, a retinal implant chip smaller than a grain of rice. Designed to be surgically placed within the eye and paired with camera-equipped glasses, PRIMA aims to restore functional vision to individuals suffering from advanced macular degeneration. Science Corporation acquired the PRIMA assets in 2024 from the French company Pixium Vision, refined the technology, and completed clinical trials initiated by the previous owner. The startup reports that its own clinical results are distinct and promising. In trials involving 47 patients across Europe and the United States, 80% demonstrated significant improvements in visual acuity, enabling them to read letters, numbers, and words. Hodak noted that this represents the first definitive proof of restored fluency in reading among blind patients. The technology's potential was further highlighted when the device appeared on the cover of Time magazine. Although a commercial launch date remains undefined, the regulatory pathway is progressing. Science Corporation has submitted a CE mark application to the European Union and projects approval by mid-2026, which would position the firm as the first BCI company with a market-ready product. Germany is expected to be the initial launch market due to its established frameworks for early access to new medical technologies. Meanwhile, discussions with the U.S. Food and Drug Administration are ongoing. Furthermore, the company plans to expand its PRIMA trial program to address Stargardt disease and retinitis pigmentosa, which are leading causes of vision loss in young adults. The newly raised capital will fund the commercialization of PRIMA and support the startup's broader research initiatives. This includes a biohybrid neural interface program that utilizes engineered neurons grown from stem cells on a specialized substrate, designed to form biological connections with the brain's surface. Additionally, Science Corporation is developing a new business unit called Vessel, an organ preservation platform. This technology aims to miniaturize perfusion systems, allowing organs to be transported via commercial flights or maintained by patients at home rather than in intensive care units. The Series C round included participation from a mix of existing and new investors, including Lightspeed Venture Partners, Khosla Ventures, Y Combinator, Quiet Capital, and IQT, a nonprofit firm specializing in solutions for government agencies such as the FBI and CIA. With this latest infusion, Science Corporation's total funding reaches $490 million, and the company currently employs 150 people.